Looking Ahead to Change: Little by Little
I don't make New Year's Resolutions. I don't think I ever really did, but the last decade or two would have been enough to stifle that impulse. I've just been too aware that I don't have that much control over what happens in my life.
Discuss the article on the Forums.

DAAO and GlyT1 inhibitors in treatment of Alzheimers, OCD, depression, schizophrenia, and more

Discussion in 'Detox: Methylation; B12; Glutathione; Chelation' started by pgoody, Jul 26, 2013.

  1. pgoody

    pgoody

    Messages:
    66
    Likes:
    33
    Here is an abstract that discusses the current thoughts behind this kind of treatment:

    https://www1.wfsbp-congress.org/guest/SciProgramSessionsList?SSN_ID=832

    Currently the top two GlyT1 inhibitors available are sarcosine (an endogenous inhibitor) and Bitopertin (which will be marketed come 2015?).

    D-amino acid oxidase (DAAO) inhibitors inhibit the breakdown of d-serine (and other D-amino acids). D-serine is an endogenous co-agonist of the NMDA glycine/d-serine site.

    A few more links:
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905773/ more in depth explanation

    https://www1.wfsbp-congress.org/guest/AbstractView?ABSID=11058 for OCD
    https://www1.wfsbp-congress.org/guest/AbstractView?ABSID=11023 for depression
    https://www1.wfsbp-congress.org/guest/AbstractView?ABSID=11059 sodium benzoate, a potential DAAO inhibiting agent
    https://www1.wfsbp-congress.org/guest/AbstractView?ABSID=12051 for Alzheimers

    There are likely other DAAO agents being tested, as I have read some material about this dating back at least 5 years. Sodium benzoate was something I just spotted on this particular site.
     

See more popular forum discussions.

Share This Page